Evaluation prevalence of Pompe disease in Iranian patients with myopathies of unknown etiology
Keywords:
Pompe disease, Proximal myopathy, hyperCKemiaAbstract
Background: Pompe disease is a rare but potentially treatable metabolic disorder having an estimated worldwide incidence of one in forty thousand live births. While the introduction of enzyme replacement therapy (ERT) has considerably increased the awareness of the disease, the delay in diagnosis is still consistent and most patients go undetected.
Objective: This study aimed to determine the prevalence of late-onset Pompe disease (LOPD) in a high-risk population, using dried blood spot (DBS) as a main screening tool.
Methods: This cross-sectional study was performed on the 93 patients who attended to the neuromuscular center of Bu-ali hospital in Tehran, Iran, during 2014-2015. Inclusion criteria were: 1) age ≥1 years, 2) proximal myopathies of unknown etiology in lower limbs or symptoms of limb girdle muscle weakness (LGMW), and 3) unexplained elevated CPK (>174). Acid α-glucosidase (GAA) activity was measured separately on DBS by fluorometric method. For the final diagnosis, GAA deficiency was confirmed by a biochemical assay in skeletal muscle, whereas genotype was assessed by GAA molecular analysis. All statistical tests were performed using the SPSS version 16. Results are presented as mean (SD) or median (IQR), as appropriate.
Results: In a 12-month period, we studied 93 cases: 5 positive samples (5.3%) were detected by DBS screening, biochemical and molecular genetic studies finally confirmed LOPD diagnosis in 3 cases (3.22%). Among the 93 patients, 100% showed hyperCKemia, 89 patients (95.7%) showed LGMW and 4 patients had symptoms of proximal myopathies in the lower limb.
Conclusions: Results from the LOPED study suggest that GAA activity requires accurate screening by DBS in all patients referred for hyperCKemia and/or LGMW.
References
Hers HG. Alpha glucosidase deficiency in generalized storage disease (pompe’s disease). Bochem J. 1963;
: 11-16. doi: 10.1042/bj0860011. PMID: 13954110, PMCID: PMC1201703.
Kishnani P, Hwu W, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter
study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006; 148: 671-6. doi:
1016/j.jpeds.2005.11.033. PMID: 16737883.
Gaeta M, Barca E, Ruggeri P, Minultoli F, Rodolico C, Mazziotti S, et al. Late onset pompe diseas
(LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function. Mol
Genet Metab. 2013; 110: 290-6. doi: 10.1016/j.ymgme.2013.06.023. PMID: 23916420.
Toscano A, Montagnese F, Musumeci O. Early is better? A new algorithm for early diagnosis in late onset
Pompe disease (LOPD). Acta Myol. 2013; 32(2): 78-81. PMCID: PMC3866896.
Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Timing of diagnosis of patients
with Pompe disease: data from the Pompe registry. Am J Med Genet A. 2013; 161: 2431-43. doi:
1002/ajmg.a.36110. PMID: 23997011.
Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference.
Pediatr Neonatol. 2013; 54: 219-27. doi: 10.1016/j.pedneo.2013.03.009. PMID: 23632029.
Kallwass H, Carr C, Gerrein J, Titloe M, Pomponio R, Bali D, et al. Rapid diagnosis of late onset Pompe
disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. Mol Genet Metab. 2007;
: 449-52. doi: 10.1016/j.ymgme.2006.12.006. PMID: 17270480.
La marca G, Casetta B, Malvagia S, Guerrini R, Zammarchi E. New strategy for screening of lysosomal
storage dosorders:the use of online trapping-and-cleanup liquid chromatography/mass spectrometry. Anal
Chem. 2009; 81(15): 6113-21. doi: 10.1021/ac900504s. PMID: 19555116.
Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, et al. Screening for Pompe disease
using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve. 2009;
(1): 32-6. doi: 10.1002/mus.21376. PMID: 19533645.
Lukacs Z, Nieves Cobos P, Mengel E, Hartung R, Beck M, Deschauer M, et al. Diagnostic efficacy of the
fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared
with lymphocytes-possibilitynfor newborn screening. J Inherit Metab Dis. 2010; 33(1): 43-50. doi:
1007/s10545-009-9003-z. PMID: 20033296.
Spada M, Porta F, Vercelli L, Pagliardini V, Chiado-Piat L, Boffi P. Screening for later-onset Pompe’s
disease in patients with paucisymptomatic hyperCKaemia. Mol Genet Metab. 2013; 109: 171-3. doi:
1016/j.ymgme.2013.03.002. PMID: 23566438.
Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, et al. Frequency of glycogen
storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum
Genet. 1999; 7(6): 713-6. doi: 10.1038/sj.ejhg.5200367. PMID: 10482961.
Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. Early detection of Pompe disease
by newborn screening is feasible: resulys from the Taiwan screening program. Pediatrics. 2008; 122(1): 39- 45. doi: 10.1542/peds.2007-2222. PMID: 18519449.
Yang CF, Liu HC, Hsu TR, Tsai FC, Chiang SF, Chiang CC, et al. A large-scale nationwide newborn
screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med
Genet A. 2014; 164: 54-61. doi: 10.1002/ajmg.a.36197. PMID: 24243590.
Preisler N, Lukacs Z, Vinge L, Madseh KL, Hansen RS. Late-onset Pompe disease is prevalent in
unclassified limb-girdle muscular dystrophies. Mol Gen Metab. 2013; 110(3): 287-9. doi:
1016/j.ymgme.2013.08.005. PMID: 24011652.
Frenandez C, de Paula A, Figarella-Branger D, Kranha M, Giorqi R. Diagnostic evaluation of clinically
normal subjects with chronic hyperCKaemia. Neurology. 2006; 66: 1585-7. doi:
1212/01.wnl.0000216144.69630.6e. PMID: 16717227.
Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease. Muscle biopsy vs blood-based assays. JAMA
Neurol. 2013; 70: 923-7. doi: 10.1001/2013.jamaneurol.486. PMID: 23649721.
Pompe Disease Diagnostic Working Group, Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen
E, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an
international consensus meeting. Mol Genet Metab. 2008; 93(3): 275-81. doi:
1016/j.ymgme.2007.09.006. PMID: 18078773.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
